Laboratorios Saval S.A. has acquired a pharmeceutical processing plant
Laboratorios Saval S.A. has acquired a pharmeceutical processing plant in Costa Rica from Laboratorios Stein S.A.
Laboratorios Saval is a Chilean company with more than 80 years of history. It began its history in Spain in the 1930s and today, has a presence in more than 14 countries. The company manufactures and distributes pharmaceuticals in the areas of infectious diseases, ophthalmology, immunology and oncology, gastroenterology, bronchopulmonary, cardiology, psychiatry and rheumatology.
Laboratorios Stein is a leading company in Latin America in the commercialization and distribution of highly complex pharmaceutical products including innovative products, biosimilars and complex generics.
Oaklins’ team in Chile acted as financial advisor to Laboratorios Saval in this transaction.
Contáctese con el equipo de la transacción
Transacciones relacionadas
Bayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Conozca másVivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
Conozca másCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Conozca más